 The actions of CysLT1 receptor antagonists (montelukast, zafirlukast and pranlukast) are competitive, as such they hinder the actions of leukotrienes.They prevent different types of asthmatic responses as well as having effects on bronchoconstriction and inflammation.Adverse effects often follow the use of these medications.